The Montreal-based Myeloma Canada Research Network Receives Significant Funding Support from Karyopharm Therapeutics

31 August 2015

Myeloma Canada has received its first major contribution by a pharmaceutical or biotechnology company supporting the formalization of the Myeloma Canada Research Network (MCRN). Karyopharm Therapeutics has made a significant donation to further the development of the MCRN in helping achieve its goal of advancing collaborative, pan-Canadian myeloma clinical trial research.

Click here for full article